The 2022-23 Leaf Exotic Walt Frazier Elephant serial-numbered autograph card (EA-WF1) features a unique elephant-themed design and manufacturer-applied sticker signature.
No condition-by-condition breakdown has been recorded for this card yet.
Product Overview
Description
The 2022-23 Leaf Exotic Walt Frazier Elephant serial-numbered autograph card (EA-WF1) stands out in the modern sports card landscape with its distinctive thematic design. As part of the Leaf Exotic series, this release pairs the legendary New York Knicks guard with a creative elephant motif that differentiates it from standard parallel treatments. The card features a manufacturer-applied autograph sticker, ensuring a pristine presentation of Frazier's signature without the wear often associated with in-person signings. The Elephant variation adds a layer of intrigue, appealing to those who seek more than just a standard base card. Being serial numbered, each copy holds a unique place in the print run, adding a sense of exclusivity to the ownership experience. This card serves as a vibrant tribute to Frazier's storied career with the Knicks, capturing his essence through a creative and engaging lens. For investors and hobbyists alike, the combination of Leaf's reputation for quality, Frazier's enduring popularity, and the unique Elephant parallel makes this a compelling addition to any collection. The sticker autograph format ensures the signature remains visible and protected, maintaining its integrity over time. Whether you are a dedicated Knicks fan or a broader basketball card collector, this piece offers a stylish and distinctive way to honor one of the game's all-time greats.
Last Listing Activity
9/17/26
Seller Action
Have one of these to sell?
We'll pre-fill the product details from this catalog entry, so your listing lands on this exact page. Just add photos of your copy, pick its condition, and set your price.
Product Specs
Card Details
The catalog profile below summarizes the card identity, featured subject, and notable collectible traits.
Estimated delivery September 30, 2026 - October 2, 2026
Collector Ownership
Owned by Collectors
See how many public collections currently include this card.
0 collectors have this card
SuperCatch Expert Analysis
Market Value Insight
Walt Frazier's presence in the 2022-23 Leaf Exotic set places this card in a premium tier relative to standard base issues, as autographed serial-numbered cards from boutique Leaf releases consistently command a significant premium over mass-produced alternatives. With only one active listing currently available, the market is effectively illiquid, which can either suppress buyer confidence or amplify perceived scarcity depending on collector demand. Frazier's Hall of Fame status and iconic association with the championship-era New York Knicks sustains strong collector interest, particularly among regional and vintage basketball enthusiasts.
Rarity Breakdown
Leaf Exotic is a limited-production brand by design, with serial-numbered autographs typically featuring very low print runs that keep raw copies scarce and graded population reports thin. The combination of a serial number and an autograph places this card in a higher-tier insert category rather than a base parallel, which meaningfully narrows the available supply. With only one active listing on the market, the graded population is likely minimal, and raw copies may be equally difficult to source, reinforcing the card's low-census appeal.
Investment Outlook
Frazier's Hall of Fame pedigree and his enduring cultural relevance as a Knicks legend provide a stable floor for long-term collector demand, particularly as vintage NBA nostalgia continues to drive interest in players from the 1970s championship era. Leaf autograph products have seen growing grading submission trends among collectors seeking to authenticate and encapsulate low-print-run signatures, which could gradually tighten an already limited graded population. The single active listing suggests the market is in an accumulation phase rather than a distribution phase, which historically aligns with favorable entry conditions for patient investors.
